Patent ID: 8410132

Claim:
A method of modulating CFTR activity comprising the step of contacting said CFTR with a compound of formula (VA): or a pharmaceutically acceptable salt or tautomer thereof, wherein: k is 0 or 1; Each R 1 is independently H, halo or C 1-3 alkyl; Each W is a bond or a C 1-6 straight or branched aliphatic chain wherein up to 2 of the carbon units are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR′—, —CONR′NR′—, —CO 2 —, —OCO—, —NR′CO 2 —, —O—, —NR′CONR′—, —OCONR′—, —NR′NR′, —NR′NR′CO—, —NR′CO—, —S—, —SO, —SO 2 —, —NR′—, —SO 2 NR′—, —NR′SO 7 —, or —NR′SO 2 NR′—; and R W is independently R′, halo, —NO 2 , —CN, —CF 3 , or —OCF 3 ; m is 0-5; Each R′ is hydrogen or a group selected from a C 1-8 aliphatic, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R′ are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and Each of Z 1 or Z 2 is independently —CH—, —CR 1 —, or N, and at least one of Z 1 or Z 2 is N.